Invitae (NYSE: NVTA) has grown revenue over time, but the genetic testing specialist has failed to turn that into profit. Instead, the company burned through more and more cash, prompting it to launch ...

Invitae’s (NVTA) significant revenue growth in its most recently reported quarter and its success in bringing customized health monitoring into the mainstream have heightened investor optimism around ...

Invitae's shares have plummeted as the company slashed its growth forecast to avoid bankruptcy. Revenue for Q2 was slightly above estimates but down 12% YoY, and analyst revenue estimates have ...

Invitae's business has been growing rapidly and there's still more growth on the horizon. The beaten-up stock is a risky buy given its significant losses and persistent cash burn. There's significant ...

Invitae, a genetic testing services provider, reported Q1 2023 revenue of $117.4 million, down from Q1 2022's $123.7 million due to exited businesses and geographies. However, after accounting for ...

Bull case: Invitae has launched a plan to reach positive cash flow as soon as possible. Any progress could drive share gains. Bear case: Invitae comes with too much risk in an uncertain market. Could ...

Shares of molecular diagnostics company Invitae (NYSE: NVTA) climbed 10.7% on Tuesday. At this point, investors may be more willing to take a flyer on Invitae, especially since Cathie Wood, the CEO ...

Shares of the genetic testing company have more than doubled in less than a week. It likely isn’t durable. It was also truly bizarre. Invitae announced a strategic pivot and provided financial ...

Invitae Corporation (NYSE:NVTA), backed by SoftBank Group (OTC:SFTBY) (OTC:SFTBF), is reportedly on the brink of filing for bankruptcy in the coming weeks. The San Francisco-based medical genetics ...

Invitae (NYSE: NVTA) shares have plummeted more than 80% this year. The genetic testing company has grown revenue over the years, but it hasn't been able to turn that revenue into profit. Instead, ...